Alogliptin, a dipeptidylpeptidase-4 inhibitor, for patients with diabetes mellitus type 2, induces tolerance to focal cerebral ischemia in non-diabetic, normal mice

[1]  K. Iihara,et al.  The Role of the Host Defense System in the Development of Cerebral Vasospasm: Analogies between Atherosclerosis and Subarachnoid Hemorrhage , 2012, European Neurology.

[2]  S. Gandhi,et al.  Vildagliptin selectively ameliorates GLP-1, GLUT4, SREBP-1c mRNA levels and stimulates β-cell proliferation resulting in improved glucose homeostasis in rats with streptozotocin-induced diabetes. , 2012, Journal of diabetes and its complications.

[3]  J. Huh,et al.  Sitagliptin increases tau phosphorylation in the hippocampus of rats with type 2 diabetes and in primary neuron cultures , 2012, Neurobiology of Disease.

[4]  S. Briyal,et al.  Repeated administration of exendin-4 reduces focal cerebral ischemia-induced infarction in rats , 2012, Brain Research.

[5]  Kerstin Iverfeldt,et al.  Glucagon-like peptide-1 receptor activation reduces ischaemic brain damage following stroke in Type 2 diabetic rats , 2011, Clinical science.

[6]  M. Woodin,et al.  Endogenous GABAA and GABAB receptor-mediated electrical suppression is critical to neuronal anoxia tolerance , 2011, Proceedings of the National Academy of Sciences.

[7]  T. Miyata,et al.  NDRG4 Protein-deficient Mice Exhibit Spatial Learning Deficits and Vulnerabilities to Cerebral Ischemia* , 2011, The Journal of Biological Chemistry.

[8]  E. Lo,et al.  Decreased Cerebrovascular Brain-Derived Neurotrophic Factor–Mediated Neuroprotection in the Diabetic Brain , 2011, Diabetes.

[9]  N. Hattori,et al.  Exendin-4, a glucagon-like peptide-1 receptor agonist, provides neuroprotection in mice transient focal cerebral ischemia , 2011, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[10]  L. Scott.  Alogliptin , 2010, Drugs.

[11]  M. Mattson,et al.  Enhancing the GLP‐1 receptor signaling pathway leads to proliferation and neuroprotection in human neuroblastoma cells , 2010, Journal of neurochemistry.

[12]  C. Hölscher,et al.  Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer's disease. , 2010, European journal of pharmacology.

[13]  Sohita Dhillon.  Sitagliptin , 2010, Drugs.

[14]  H. Diener,et al.  Prediction of Recurrent Stroke and Vascular Death in Patients With Transient Ischemic Attack or Nondisabling Stroke: A Prospective Comparison of Validated Prognostic Scores , 2010, Stroke.

[15]  W. Cefalu.  The Physiologic Role of Incretin Hormones: Clinical Applications , 2010, The Journal of the American Osteopathic Association.

[16]  M. Rizzo,et al.  Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors , 2009, Expert opinion on investigational drugs.

[17]  C. Bult,et al.  Aging in inbred strains of mice: study design and interim report on median lifespans and circulating IGF1 levels , 2009, Aging cell.

[18]  M. Mattson,et al.  GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism , 2009, Proceedings of the National Academy of Sciences.

[19]  M. Greenberg,et al.  A Biological Function for the Neuronal Activity-Dependent Component of Bdnf Transcription in the Development of Cortical Inhibition , 2008, Neuron.

[20]  Y. Nakano,et al.  Genetic increase in brain-derived neurotrophic factor levels enhances learning and memory , 2008, Brain Research.

[21]  M. Mattson,et al.  Glutamate and Neurotrophic Factors in Neuronal Plasticity and Disease , 2008, Annals of the New York Academy of Sciences.

[22]  Guang-yi Zhang,et al.  Neuroprotection of γ‐aminobutyric acid receptor agonists via enhancing neuronal nitric oxide synthase (Ser847) phosphorylation through increased neuronal nitric oxide synthase and PSD95 interaction and inhibited protein phosphatase activity in cerebral ischemia , 2008, Journal of neuroscience research.

[23]  D. Kassel,et al.  Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys. , 2008, European journal of pharmacology.

[24]  K. Takeuchi,et al.  Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice. , 2008, European journal of pharmacology.

[25]  H. Naritomi,et al.  Repeated application of an electric field increases BDNF in the brain, enhances spatial learning, and induces infarct tolerance , 2008, Brain Research.

[26]  D. Drucker,et al.  Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent Pathways , 2008, Circulation.

[27]  Joyce Chou,et al.  TrkB agonists ameliorate obesity and associated metabolic conditions in mice. , 2008, Endocrinology.

[28]  D. Kassel,et al.  Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. , 2007, Journal of medicinal chemistry.

[29]  E. Carbone,et al.  Brain-Derived Neurotrophic Factor Enhances GABA Release Probability and Nonuniform Distribution of N- and P/Q-Type Channels on Release Sites of Hippocampal Inhibitory Synapses , 2005, The Journal of Neuroscience.

[30]  S. Ibayashi,et al.  Ten year recurrence after first ever stroke in a Japanese community: the Hisayama study , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[31]  Kenichi Murao,et al.  Spreading depression induces long-lasting brain protection against infarcted lesion development via BDNF gene-dependent mechanism , 2004, Brain Research.

[32]  P. Calabresi,et al.  Coactivation of GABAA and GABAB Receptor Results in Neuroprotection During In Vitro Ischemia , 2004, Stroke.

[33]  GiorgioBernardi,et al.  Coactivation of GABAA and GABAB Receptor Results in Neuroprotection During In Vitro Ischemia , 2004 .

[34]  W. Banks,et al.  Glucagon-like peptide-1 receptor is involved in learning and neuroprotection , 2003, Nature Medicine.

[35]  I. Nagata,et al.  Evaluation of MCAO stroke models in normotensive rats: standardized neocortical infarction by the 3VO technique , 2003, Experimental Neurology.

[36]  A. Tsuchida,et al.  Antiobesity and antidiabetic effects of brain-derived neurotrophic factor in rodent models of leptin resistance , 2003, International Journal of Obesity.

[37]  N. Greig,et al.  A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells. , 2002, The Journal of pharmacology and experimental therapeutics.

[38]  I. Mizuta,et al.  Infarct tolerance accompanied enhanced BDNF-like immunoreactivity in neuronal nuclei , 2000, Brain Research.

[39]  H. Sakai,et al.  Infarct tolerance induced by intra-cerebral infusion of recombinant brain-derived neurotrophic factor , 2000, Brain Research.

[40]  I. Nakahara,et al.  Combination of intraischemic and postischemic hypothermia provides potent and persistent neuroprotection against temporary focal ischemia in rats. , 1999, Stroke.

[41]  D. Smith,et al.  A role for glucagon-like peptide-1 in the central regulation of feeding , 1996, Nature.

[42]  E. Halpern,et al.  Secondary Elevation of Extracellular Neurotransmitter Amino Acids in the Reperfusion Phase following Focal Cerebral Ischemia , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[43]  Y. Barde,et al.  Brain-derived neurotrophic factor prevents neuronal death in vivo , 1988, Nature.

[44]  L. Pitts,et al.  Evaluation of 2,3,5-triphenyltetrazolium chloride as a stain for detection and quantification of experimental cerebral infarction in rats. , 1986, Stroke.

[45]  W. Calder,et al.  Body size, mortality, and longevity. , 1983, Journal of theoretical biology.

[46]  M. Mattson,et al.  GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease. , 2010, Journal of Alzheimer's disease : JAD.

[47]  N. Woo,et al.  Persistent neural activity in the prefrontal cortex: a mechanism by which BDNF regulates working memory? , 2008, Progress in brain research.

[48]  Z. Zhang,et al.  Ischemia Prolonged Mild Hypothermia Therapy Protects the Brain Against Permanent Focal , 2000 .